Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameHansoh Pharma
Stock Code03692
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是為數不多的以研發為驅動的中國製藥公司之一,在中樞神經系統疾病、抗腫瘤、抗感染及糖尿病等領域擁有廣泛、多元化及領先的藥物組合,並專注於消化道及心血管治療領域。
Listing Date2019-06-14
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇連雲港經濟技術開發區東晉路9號(郵編:222069)
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.hspharm.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 14.26 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-05-31 to 2019-06-05
Global Offering Shares551,280,000 shares
HK Public Offer Shares (Initial)38,590,000 shares (7.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)512,690,000 shares (93.0%)
Offer Ratio~7.0%
Total Shares Post-IPO5,705,919,200 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share34.4%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 7,861,252,800

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 208.22B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣19.030億元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 214,900,000
Listing Expenses / Funds Raised~2.73%
Total Pre-IPO Investment248,581,849美元(相當於人民幣1,682,278,000元)

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018
Revenue 5,432,9606,185,5377,722,278
Cost of sales -397,279-455,171-603,100
Gross profit 5,035,6815,730,3667,119,178
Other income and gains, net 85,81193,23077,953
Selling and distribution expenses -2,378,040-2,704,200-3,208,680
Administrative expenses -537,972-614,075-790,158
Operating profit 1,807,6891,932,7912,309,325
Net finance costs -3,411
Profit before tax 1,804,2781,932,7912,309,325
Income tax expense -328,244-337,318-406,277
Profit for the year 1,476,0341,595,4731,903,048
Profit attributable to owners 1,476,0341,595,4731,903,048
Balance Sheet
Item 201620172018
Cash and cash equivalents 208,699266,444964,831
Trade and bills receivables 1,723,5352,192,5182,645,207
Inventories 353,051439,355479,664
Total current assets 3,463,6994,417,8676,684,185
Total assets 4,820,9515,874,0488,414,371
Total current liabilities 1,811,9641,227,6744,503,785
Total liabilities 1,846,6131,355,3585,946,473
Total equity 2,974,3384,518,6902,467,898
Equity attributable to owners 2,974,3374,518,6892,467,897
Cash Flow Statement
Item 201620172018
Net cash from operating activities 1,246,5071,402,2522,072,227
Net cash from investing activities 829,538-614,271-1,388,744
Depreciation of PP&E 115,358131,382148,624
Amortisation of intangible assets 3,6793,9647,641
Purchase of PP&E -238,926-256,346-381,378
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 19.5
First Day OpenHK$ 16.3
First Day Change36.75%
First Day Volume138363000.0
First Day Turnover2452210000.0
Use of Proceeds
1、所得款項凈額約45%或3,438百港元用于研發(包括我們現有及未來的國內及海 外藥物開發項目)、擴充我們的研發團隊及于研發技術的投資; 2、約25%或1,910百港元用于生產體系,建設新生產線,升級現有生產設施并提 高其自動化水平; 3、約20%或1,528百港元用于銷售及學術推廣,以配合新產品上市,尤其是四種 將自2019年至2020年上市的創新藥; 4、余款約10%或764百港元將用于撥付我們的營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 Citigroup Global Markets Asia Limited CE AAA137
Overall Coordinators (5)
Morgan Stanley Asia Limited CE AAD291 Citigroup Global Markets Asia Limited CE AAA137 UBS Securities Hong Kong Limited CE BIN466 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (6)
Morgan Stanley Asia Limited CE AAD291 Citigroup Global Markets Asia Limited CE AAA137 UBS Securities Hong Kong Limited CE BIN466 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (7)
Morgan Stanley Asia Limited CE AAD291 Citigroup Global Markets Asia Limited CE AAA137 UBS Securities Hong Kong Limited CE BIN466 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Ally Bridge LB Healthcare Master Fund Limited 313,976,680 HKD — 3.99% — 6 months 2019-12-14
2 Boyu Capital Opportunities Master Fund 470,950,760 HKD — 5.99% — 6 months 2019-12-14
3 Cormorant Asset Management, LP 196,217,600 HKD — 2.50% — 6 months 2019-12-14
4 GIC Private Limited 549,466,320 HKD — 6.99% — 6 months 2019-12-14
5 Hillhouse Funds 228,758,920 HKD — 2.91% — 6 months 2019-12-14
6 Prime Capital Funds 313,976,680 HKD — 3.99% — 6 months 2019-12-14
7 Vivo Funds 156,974,080 HKD — 2.00% — 6 months 2019-12-14
8 Worldwide Healthcare Trust PLC 313,976,680 HKD — 3.99% — 6 months 2019-12-14
9 上海医药(香港)投资有限公司 156,974,080 HKD — 2.00% — 6 months 2019-12-14

Directors & Management

PositionChinese nameEnglish Name
Chairman鍾慧娟—
Company Secretary鍾勝利、李昕穎—
No director data available.

Major Shareholders

Major Shareholders & HoldingsStellar Infinity緊隨全球發售完成後持股約68.35%,連同Sunrise Investment、Sunrise Trust受託人、孫小姐及鍾女士被視為控股股東;Apex Medical持股約16.65%,由岑均達先生全資擁有。
About this page

This page shows Hansoh Pharma (03692) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect